Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.

Molecular diagnosis & therapy - 1 Aug 2017

Yeung Kay T, More Soham, Woodward Brian, Velculescu Victor, Husain Hatim

Abstract excerpt

Targeted therapies have changed the treatment landscape of non-small cell lung cancer over the past decade. Analyses of cell free circulating tumor DNA (ctDNA) provide a non-invasive and robust approach for cancer diagnosis and prognosis, real-time monitoring of treatment response, and the identification of appropriate therapeutic targets based on the detection of tumor genetic aberrations. Recent improvements in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Early Detection of Cancer

Share to Molecular Targeted Therapy

Share to Neoplasm Proteins

Share to Protein Kinase Inhibitors

Share to Recurrence

Source

Identifiers

PMID: 28337711
DOI: 10.1007/s40291-017-0260-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.PMID 28337711Read ↗

Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response.Semantic proximity Read ↗

Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient ManagementSemantic proximity Read ↗

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.Semantic proximity Read ↗

Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.Semantic proximity Read ↗

Circulating Tumour DNA in EGFR-Mutant Non-Small-Cell Lung CancerSemantic proximity Read ↗

Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challengesSemantic proximity Read ↗

Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.Semantic proximity Read ↗

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancerSemantic proximity Read ↗

Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectivesSemantic proximity Read ↗

Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.